23andMe Holding Co. (Nasdaq: ME), a leading genetic health and
biopharmaceutical company, in collaboration with 20 lung cancer
advocacy organizations, today announced a new study to help advance
research in lung cancer. The focus of the Lung Cancer Genetics
Study is to better understand the genetics of people with lung
cancer in order to improve detection, risk reduction, and care.
While recent developments in tumor genetic testing and targeted
therapies have provided hope and years of survival to many lung
cancer patients, lung cancer remains the number one cause of cancer
deaths in both men and women in the United States. Yet, much
remains unknown about the disease and its causes.
“There is a great need to better define the underlying genetics
of lung cancer,” said Courtney Granville, Chief Scientific Officer
at GO2 for Lung Cancer. “We are privileged to stand together with
the research and patient advocacy communities to contribute to this
effort to better define inherited risk for lung cancer and inform
our ability to prevent, diagnose, and treat people. Ultimately, the
learnings from this study will improve outcomes for future
generations.”
The de-identified data from the study will be made available to
approved researchers, and access to the scientific database will be
available to nonprofit researchers and institutions at no cost.
Sobering lung cancer statistics only tell part of the
storyDespite advances in treatment options, lung cancer
remains a critical area of unmet need:
- In 2020, lung cancer took more lives in the United States than
breast, colorectal, and prostate cancers combined.
- One in 16 people in the United States will be diagnosed with
lung cancer in their lifetime.
- It is estimated that in 2024, 234,000 new people will be
diagnosed with lung cancer in the United States.
- While lung cancer accounts for 12% of all new cancer diagnoses,
it accounts for 20% of cancer deaths.
- Despite being the deadliest cancer, lung cancer research is
underfunded compared to other cancer types.
- Early detection of lung cancer through screening can
dramatically improve the long-term survival rate. Only 25% of all
people diagnosed with lung cancer will survive 5 years or more, but
for those whose cancer was diagnosed through annual screening by CT
scan, the 20-year survival rate is 81%.
- In people diagnosed at 55 years of age or younger, lung cancer
is more common in women than men. Among people with lung cancer who
have never smoked, approximately two-thirds are women, making women
who have not smoked more than twice as likely to develop lung
cancer as men who have not smoked.
Behind every devastating statistic are people from communities
across the U.S. impacted by lung cancer. Through this
collaboration, advocacy organizations, lung cancer survivors and
advocates, and 23andMe hope ultimately to help advance research
toward finding a cure for this disease.
“LUNGevity Foundation is excited to partner on this
community-driven project,” said Upal Basu Roy, Vice President of
Research at LUNGevity Foundation. “As a researcher and a patient
advocate, I'm most excited about how the data collected in this
study could be leveraged to help patients in the future. For
example, it could help researchers identify new drug targets and
mechanisms for drug development or find ways to address side
effects proactively.”
This study includes the following collaborators: ALK Positive,
Biomarker Collaborative, BRAF Bombers, EGFR Resisters, Exon 20
Group, Free ME from Lung Cancer, GO2 for Lung Cancer, The Happy
Lungs Project, International Cancer Advocacy Network, KRAS Kickers,
Lung Cancer Foundation of America, Lung Cancer Research Foundation,
LUNGevity Foundation, MET Crusaders, NTRKers, Oncogene Cancer
Research, PDL1 Amplifieds, RET Positive, RET Renegades, The
ROS1ders, and Troper Wojcicki Philanthropies.
“Studying the genetics of lung cancer can help us understand
risks, improve early detection, and develop better treatments. This
collaborative effort unites patients, advocates, doctors, and
researchers,” said Jill Feldman, patient advocate and co-founder of
the EGFR Resisters. “By making the data securely accessible to
researchers worldwide, the Lung Cancer Genetics Study increases our
chances of breakthroughs that can save lives.”
Enhancing lung cancer researchThe 23andMe
research platform will enable consented participants to come
together to provide critical data for scientists studying lung
cancer. Research data will include genetic information and
self-reported information about each participant's unique
experiences (using responses from online surveys), as well as
additional data sources such as medical records and tumor biomarker
information. Through this study, advocacy organizations, advocates,
and 23andMe aim to enhance research into lung cancer by bringing
together a large group of people to better understand how genetics
may influence lung cancer, expanding the geographic reach of the
research study by enabling participation from home, and removing
some of the time and cost barriers that can slow progress.
How this study can help further researchThe
goal of the study is to recruit 10,000 people who have been
diagnosed with lung cancer, with no restrictions on the type of
lung cancer, stage of disease, gender, smoking status, biomarker,
or other variables. The lung cancer genetics study is recruiting
individuals who are 18 years or older, live in the United States,
and have been diagnosed with lung cancer. Participants in the
study can receive the 23andMe kits at no cost.
“Through the launch of the Lung Cancer Genetics Study, we hope
to fill an unmet need for a comprehensive database that bridges the
gap between genetic, clinical, and patient-reported data,” said
Anne Wojcicki, Co-Founder and CEO of 23andMe. “Because lung cancer
affects people from all communities, it's important for this
research to truly reflect the diversity of those impacted by the
disease. This collaborative effort unites survivors, caregivers,
researchers, and advocates who are all dedicated to improving the
treatment and care of lung cancer.”
The Lung Cancer Genetics Study is made possible by support from
Troper Wojcicki Philanthropies (TWP). Troper Wojcicki
Philanthropies deploys philanthropy and mission-related investments
to organizations that are accelerating cancer research, tackling
climate change, and advancing human rights. Since 2006, TWP has
committed more than $100M to researchers, academics, and
entrepreneurs committed to making a positive impact on the world.
For the last 15 years, 30% of TWP’s funding has been dedicated to
advancing cancer research.
For more information on the study, please see the Lung Cancer
Genetics Study landing page.
About 23andMe23andMe is a genetics-led consumer
healthcare and biopharmaceutical company empowering a healthier
future. For more information, please visit www.23andMe.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including. All
statements, other than statements of historical fact, included or
incorporated in this press release are forward-looking statements.
The words "believes," "anticipates," "estimates," "plans,"
"expects," "intends," "may," "could," "should," "potential,"
"likely," "projects," “predicts,” "continue," "will," “schedule,”
and "would" or, in each case, their negative or other variations or
comparable terminology, are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements are
predictions based on 23andMe’s current expectations and projections
about future events and various assumptions. 23andMe cannot
guarantee that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe’s forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as filed with the Securities and Exchange
Commission, and as revised and updated by our Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. The statements made
herein are made as of the date of this press release and, except as
may be required by law, 23andMe undertakes no obligation to update
them, whether as a result of new information, developments, or
otherwise.
ContactsMedia: press@23andMe.comInvestor
Relations: investors@23andMe.com
23andMe (NASDAQ:ME)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
23andMe (NASDAQ:ME)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024